Multiple Myeloma medicine: Natco Pharma unveils Pomalidomide under brand NAT-POMALIDOMIDE in Canada
Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells.
Hyderabad: Natco Pharma Limited today announced the launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST brand in the country approved by Health Canada.
Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients with multiple myeloma.
Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells. It is the second most common form of blood cancer in Canada with about 8,000 Canadians living with myeloma.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules and available through the RevAid risk management platform.
RevAid and POMALYST are trademarks of Celgene Corporation.
Read also: Natco Pharma announces submission of ANDA with USFDA for generic version of Olaparib Tablets
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. It is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). Its focus is primarily on niche therapeutic areas and complex products. Natco markets and distributes products in over 40 countries. The company sells its FDF products in the United States, India, Europe, and the rest of the world (“RoW”).
Read also: Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India
Natco Pharma manufactures API products which are primarily used for captive consumption in the company's FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, the company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco has eight manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma unveils first generic version of Pomalyst capsules in Australia
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd